FDA Approves New Powerful Nasal Spray to Reverse Opioid Overdoses

Opvee, a nasal spray version of nalmefene, received FDA approval to reverse overdoses from synthetic opioids like fentanyl that remain in the body longer.
Opvee acts more quickly and has longer-lasting effects than the leading overdose reversal drug naloxone but may cause intense, prolonged withdrawal symptoms.
While the more potent Opvee achieved similar results to naloxone in studies, some experts argue naloxone has proven effective and cheaper.
The new spray will be available by prescription for use in health care and community settings to counter overdoses that claimed over 100,000 lives last year.
Opvee's maker projects $150 million to $250 million in annual sales, raising concerns about costs to taxpayers and those receiving emergency overdose care.